Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial

BACKGROUND: Retinopathy of prematurity (ROP) still represents one of the leading causes of visual impairment in childhood. Systemic propranolol has proven to be effective in reducing ROP progression in preterm newborns, although safety was not sufficiently guaranteed. On the contrary, topical treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippi, Luca, Cavallaro, Giacomo, Berti, Elettra, Padrini, Letizia, Araimo, Gabriella, Regiroli, Giulia, Bozzetti, Valentina, De Angelis, Chiara, Tagliabue, Paolo, Tomasini, Barbara, Buonocore, Giuseppe, Agosti, Massimo, Bossi, Angela, Chirico, Gaetano, Aversa, Salvatore, Pasqualetti, Roberta, Fortunato, Pina, Osnaghi, Silvia, Cavallotti, Barbara, Vanni, Maurizio, Borsari, Giulia, Donati, Simone, Nascimbeni, Giuseppe, la Marca, Giancarlo, Forni, Giulia, Milani, Silvano, Cortinovis, Ivan, Bagnoli, Paola, Dal Monte, Massimo, Calvani, Anna Maria, Pugi, Alessandra, Villamor, Eduardo, Donzelli, Gianpaolo, Mosca, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513165/
https://www.ncbi.nlm.nih.gov/pubmed/28709412
http://dx.doi.org/10.1186/s12887-017-0923-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513165/
https://www.ncbi.nlm.nih.gov/pubmed/28709412
http://dx.doi.org/10.1186/s12887-017-0923-8

Ejemplares similares